Clostridium difficile (C. difficile) is one of the most threatening bacteria globally, causing high mortality and morbidity in humans and animals, and is considered a public health threat that requires urgent and aggressive action. Interruption of the human gut microbiome and the devel …

Pylum Biosciences has built a technology platform to create antibacterials that target individual strains of bacteria without affecting the microbiota. Its lead preclinical programs target Clostridioides difficile for infectious disease and Fusobacterium nucleatum for colorectal cancer.

Seres Therapeutics is selling the rights to Vowst, the microbiome drug for Clostridioides difficile (or "C. diff") that it spent more than a decade developing.

Nestle Health Science bids to take control of Seres Therapeutics’ oral microbiome product Vowst for preventing C. diff infections.

A recent study shows promise for a new antibiotic that effectively fights several bacteria while sparing the helpful bacteria that occur naturally in the gut.

This study revealed the hypoglycemic and hepatoprotective effect of CP by regulating gut microbiota composition and PPARα subcellular localization, highlighting its potential for therapeutic candidate for metabolic disorders.

The FDA has approved a fecal microbiota pill to treat infections caused by Clostridium difficile, an antibiotic-resistant bacterium.

Clostridioides difficile - also known as C. diff - is the leading cause of hospital-acquired diarrhoea and can be life-threatening for older patients.

Clostridioides difficile (C. difficile), as the major pathogen of diarrhea in healthcare settings, has become increasingly prevalent within community populations, resulting in significant morbidity and mortality. However, the therapeutic options for Clostridioides difficile infe …

Clostridioides difficile (C. difficile), as the major pathogen of diarrhea in healthcare settings, has become increasingly prevalent within community populations, resulting in significant morbidity and mortality. However, the therapeutic options for Clostridioides difficile infe …

Infections caused by Gram-negative pathogens are increasingly prevalent and are typically treated with broad-spectrum antibiotics, resulting in disruption of the gut microbiome and susceptibility to secondary infections1-3. There is a critical need for antibiotics that are selective both …

The antibiotic was effective against more than 130 multidrug-resistant bacterial strains

Clostridioides difficile has emerged as a major cause of life-threatening diarrheal disease. Conventional antibiotics used in current standards of care exacerbate the emergence of antibiotic-resistant strains and pose a risk of recurrent C. difficile infection (CDI). Thus, there is an urgent need fo …

Previous research has suggested that common antibiotics can disturb the gut microbiome.

Study offers proof-of-concept for developing antibiotics that can kill pathogenic Gram-negative bacteria while sparing beneficial species in the gut

Las Vegas Nevada United States As per DelveInsight s assessment globally Clostridium Difficile Infections pipeline constitutes 20 key companies continuously working towards developing 22 Clostridium Difficile Infections treatment therapies analysis of Clinical Trials Therapies Mechanism of Action Route of Administration ...

Clostridioides difficile - also known as C. diff - is the leading cause of hospital-acquired diarrhoea and can be life-threatening for older patients.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 21, 2024--

Vedanta Biosciences dosed the first subject in the Phase III RESTORATiVE303 trial of VE303 for preventing recurrent C. difficile infection.

Clostridium difficile infections are the most widely recognized cause of hospital acquired infectious diarrhea. There is a critical need for...

PureTech Health (GB:PRTC) has released an update. Vedanta Biosciences, an entity founded by PureTech Health, has initiated the Phase 3 RESTORATiVE303 trial for thei...

Newly discovered iron storage “ferrosomes” inside the bacterium C. diff — the leading cause of hospital-acquired infections — are important for infection in an animal model and could offer new targets for antibacterial drugs. They also represent a rare demonstration of a membrane-bound structure inside a pathogenic bacterium, upsetting the biological dogma that bacteria do not contain organelles. 

Ulcerative colitis (UC) is characterized by chronic inflammation and ulceration of the intestinal inner lining, resulting in various symptoms. Sea buckthorn berries contain a bioactive compound known as sea buckthorn polysaccharide (SBP). However, the precise mechanisms underlying the impact of SBP …

Iron storage “spheres” inside C. difficile, the leading cause of hospital-acquired infections, could offer new targets for antibacterial drugs.

Considering productivity costs in future cost-effectiveness analyses of vaccines for C. difficile and RSV will contribute to better-informed reimbursement decisions from a societal perspective.

Despite the technologies applied to food production, microbial contamination and chemical deterioration are still matters of great concern. In order to limit these phenomena, new natural approaches should be applied. In this context, the present study aimed to assess the antioxidant and anti-Clostri …

Interactions of bacteria with their viruses named bacteriophages or phages shape the bacterial genome evolution and contribute to the diversity of phages. RNAs have emerged as key components of several anti-phage defense systems in bacteria including CRISPR-Cas, toxin-antitoxin and abortive infectio …

Nature Communications - The Clostridium difficile virulence factors TcdA and TcdB contain a glucosyltransferase domain (GTD), which has both glucohydrolase (GH) and glucosyltransferase (GT)...

Due to envelope differences between Gram-positive and Gram-negative bacteria 1 , engineering precision bactericidal contractile nanomachines 2 requires atomic-level understanding of their structures; however, only those killing a Gram-negative bacterium are currently known …